QURE$23.873.92%0.90
After Hours: 23.10-0.77 -3.23%
Uniqure Nv (QURE)
Date: 2026-11-03 16:00O: 23.27H: 24.09L: 22.87C: 23.87Vol: 1.841M
Uniqure Nv stock is traded at $23.87, with a volume of 1,840,820. It is up +3.92% in the last 24 hours and up +1.75% over the past month. uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Previous Close:
$22.97
Open:
$23.27
24h Volume:
1,840,820
Relative Volume:
0.96
Market Cap:
$1.66B
Revenue:
$18.09M
Net Income/Loss:
-$208.87M
P/E Ratio:
-
EPS:
-$3.51
Net Cash Flow:
-$178.15M
1W Performance:
-1.69%
1M Performance:
+1.75%
6M Performance:
+24.78%
1Y Performance:
-30.39%
1-Day Range:
$22.87$24.09
1-Week Range:
$22.42$26.60
52-Week Range:
$8.73$51.72
Uniqure Nv Stock (QURE) Company Profile
Name
Uniqure NvSector
HealthcareIndustry
BiotechnologyPhone
1-339-970-7000Address
PAASHEUVELWEG 25A, AMSTERDAM, NetherlandsMarket Cap
Revenue
Net Income
Cash Flow
EPS
Uniqure Nv Stock (QURE) Upgrades & Downgrades
Uniqure Nv Stock (QURE) Financials Data
Uniqure Nv Stock (QURE) Insider Trading
- Kapusta Matthew CJul 02 '26CEO, Managing Director
- Transaction
- Option Exercise
- Cost
- $19.39
- #Shares
- 21,082
- Value ($)
- 408,780
- #Shares Total
- 540,309
- Kapusta Matthew CJul 02 '26CEO, Managing Director
- Transaction
- Sale
- Cost
- $45.16
- #Shares
- 21,082
- Value ($)
- 952,051
- #Shares Total
- 519,227
- Kapusta Matthew CJul 02 '26Officer
- Transaction
- Proposed Sale
- Cost
- $45.15
- #Shares
- 21,082
- Value ($)
- 951,932
- #Shares Total
- 0
- Kaye JackJun 30 '26Director
- Transaction
- Sale
- Cost
- $46.44
- #Shares
- 21,167
- Value ($)
- 983,030
- #Shares Total
- 25,996
- Abi-Saab WalidJun 30 '26Chief Medical Officer
- Transaction
- Proposed Sale
- Cost
- $46.42
- #Shares
- 30,000
- Value ($)
- 1,392,643
- #Shares Total
- 0
- Kaye JackJun 30 '26Director
- Transaction
- Proposed Sale
- Cost
- $46.44
- #Shares
- 21,167
- Value ($)
- 983,033
- #Shares Total
- 0
- Abi-Saab WalidJun 30 '26Chief Medical Officer
- Transaction
- Option Exercise
- Cost
- $5.59
- #Shares
- 10,000
- Value ($)
- 55,900
- #Shares Total
- 178,235
- Abi-Saab WalidJun 30 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $46.42
- #Shares
- 30,000
- Value ($)
- 1,392,600
- #Shares Total
- 148,235
- Kaye JackJun 30 '26Director
- Transaction
- Option Exercise
- Cost
- $23.44
- #Shares
- 21,167
- Value ($)
- 496,230
- #Shares Total
- 43,056
- Abi-Saab WalidJun 26 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $46.86
- #Shares
- 1,434
- Value ($)
- 67,197
- #Shares Total
- 168,235
